SCHEMBL1101347

SCHEMBL1101347

CCOc1cccc2cccnc12

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.68
KDM4E B2RXH2 6/20 0.68
LMNA P02545 5/20 0.68
RAB9A P51151 5/20 0.60
NPC1 O15118 4/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
GAA P10253 2/20 0.59
POLB P06746 2/20 0.56
ALDH1A1 P00352 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAPK1 P28482 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7705481 0.98 MAPT (0.66) MAPTKDM4ELMNARAB9ANPC1
Oxyquinoline SCHEMBL11594833 0.90 MMP2 (0.66) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL14825073 0.87 MAPT (0.70) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL19733317 0.86 MAPT (0.54) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL2484526 0.85 MAPT (0.66) MAPTKDM4ELMNARAB9ANPC1
Imidazole SCHEMBL28294375 0.85 MAPT (0.53) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL2484185 0.84 MAPT (0.68) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL18816623 0.83 MAPT (0.69) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL9568616 0.82 MAPT (0.66) MAPTKDM4ELMNARAB9ANPC1
SCHEMBL9671193 0.82 MAPT (0.53) MAPTKDM4ELMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111670180-A Fluoroalkenyl compounds, process for their preparation and their use PI工业有限公司 2020-09-15 CN claimed
EP-2265677-B1 CORROSION DETECTION PRODUCT AND METHOD BATTELLE MEMORIAL INSTITUTE (US) 2019-05-15 EP claimed
EP-2084163-B1 TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2017-04-12 EP claimed
EP-2039685-B1 Heterobicyclic compounds as P38 inhibitors ARRAY BIOPHARMA INC (US) 2012-12-26 EP claimed
US-8153791-B2 substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-10 US claimed
CN-101941964-A Has the Chemokine Receptors bonded heterogeneous ring compound that promotes effect ANORMED INC 2011-01-12 CN claimed
JP-4267920-B2 2009-05-27 JP claimed
CN-100376604-C Olefin polymerization catalyst and its uses CHINA PETROLEUM & CHEMICAL (CN) 2008-03-26 CN claimed
US-20070270425-A1 SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-22 US claimed
CN-1769307-A Olefin polymerization catalyst and its uses CHINA PETROLEUM & CHEMICAL (CN) 2006-05-10 CN claimed
US-6194422-B1 ANTIBIOTIC; AMYLOIDOSES THERAPY PHARMACIA & UPJOHN SPA (IT) 2001-02-27 US claimed
EP-0970080-A1 IMINO-AZA-ANTHRACYCLINONE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSIS PHARMACIA & UPJOHN S.p.A. (IT) 2000-01-12 EP claimed
WO-1998032754-A1 IMINO-AZA-ANTHRACYCLINONE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSIS PHARMACIA & UPJOHN S.P.A. (IT) 1998-07-30 WO claimed
EP-0445731-B1 Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof WARNER LAMBERT CO (US) 1996-01-10 EP claimed
US-5482938-A Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment WARNER-LAMBERT COMPANY (US) 1996-01-09 US claimed
EP-0338723-B1 NOVEL COMPOUNDS BEECHAM GROUP PLC (GB) 1993-08-04 EP claimed
US-5110828-A Treatment or prophylaxis of dementia BEECHAM GROUP P.L.C. (GB) 1992-05-05 US claimed
EP-0338723-A1 Novel compounds BEECHAM GROUP PLC (GB) 1989-10-25 EP claimed
US-4786648-A ANALGESIC WARNER-LAMBERT COMPANY (US) 1988-11-22 US claimed
EP-0271798-A2 O-Substituted tetrahydropyridine oxime cholinergic agents WARNER-LAMBERT COMPANY (US) 1988-06-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270425-A1 SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS MAP3K2, MAP3K1, MAP3K20 MAPT 3084/4885KDM4E 1680/4885LMNA 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.